NASDAQ: IBRX · Life Sciences · 6 alerts · CIK 1326110
Share price
$5.98Close, Nov 16
Market cap
$6.36B
Shares outstanding
1.06BLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ImmunityBio, Inc. filings on SEC EDGAR ↗
ImmunityBio reported total assets of $609.4 million as of September 30, 2026, an increase from $501.9 million at year-end 2025, driven primarily by a rise in marketable securities. The company maintains a significant stockholders' deficit and continues to operate as a large accelerated filer following the commercial launch of its approved product, ANKTIVA.
ImmunityBio reported Q3 2026 net product revenue of $48.7 million, a 53% increase year-over-year, driven by the adoption of ANKTIVA in the U.S. The company also highlighted a recent FDA label expansion for ANKTIVA and positive topline results from its QUILT-2.005 trial in BCG-naïve bladder cancer patients.
ImmunityBio announced that its QUILT-2.005 trial of ANKTIVA plus BCG met its primary efficacy endpoint in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC). The combination therapy showed a statistically significant improvement in efficacy compared to BCG alone, and the company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026.
The FDA has expanded the approved indication for ImmunityBio's ANKTIVA in combination with BCG to include patients with BCG-unresponsive NMIBC with papillary-only tumors. This follows the initial April 2024 approval and broadens the addressable patient population to include all patients with BCG-unresponsive NMIBC, a group that represents approximately 85% of the NMIBC population.
ImmunityBio Insider Barry J. Simon Sells $269K of Stock
Barry J. Simon sold 25,000 shares of ImmunityBio, Inc. at $10.75 a share, worth $269K in total on Oct 5, 2026. Shares held after the trade: 2,777,788 (-0.9%).
ImmunityBio Insider Cheryl Cohen Sells $851K of Stock
Cheryl Cohen sold 81,056 shares of ImmunityBio, Inc. at $10.50 a share, worth $851K in total on Oct 2, 2026. Shares held after the trade: 100,309 (-44.7%).